Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
(NASDAQ: SYRE) Delayed: 97.05 -3.27 (3.26%)
Previous Close $100.32    52 Week High $ 
Open $97.72    52 Week Low $ 
Day High $102.06    P/E N/A 
Day Low $95.31    EPS $ 
Volume 2,637,369